Drugs in Dev. Obstetrics/Gynecology (Women’s Health)
Phase IV
Lead Product(s) : Follitropin Delta
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rekovelle (follitropin delta) is a follicle-stimulating hormone made from recombinant human DNA that is used to promote follicular development in females with ovarian failure, reproduction and fertility.
Product Name : Rekovelle
Product Type : Hormone
Upfront Cash : Inapplicable
March 14, 2023
Lead Product(s) : Follitropin Delta
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Menotropins
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MEGASET-HR (high responder) study met its primary non-inferiority endpoint, with Menopur-treated patients experiencing a 35.5% ongoing pregnancy rate (OPR) per cycle start after a fresh transfer, compared to 30.7% for rFSH-treated patients
Product Name : Menopur
Product Type : Hormone
Upfront Cash : Inapplicable
May 14, 2020
Lead Product(s) : Menotropins
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
